Good work! Yervoy, Keytruda, Opdivo are biologics. However, these are drugs that stimulate an immune response against cancer cells rather than directly target tumours or cancer cells - I'm oversimplifying - depending on what kind of cancer.
PYC has the potential to produce a drug that does the latter.
Biologics are here and PYC need to hurry with their tox studies, animal trials and IND. PYC are in a race and they need to get their product to trial asap. It is this potential that makes PYC so exciting.
As an aside, Bionomics (ASX listed and I have no shareholding interest in it) also has anti cancer biologics in development - phase 1 I think. not too sure.
Big deal done between AbbVie and Stemcentrx on tumour cell targeting biologic drug IP platform.
PYC Price at posting:
1.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)